These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 33294262)
1. GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. Yan J; Zhou B; Guo L; Chen Z; Zhang B; Liu S; Zhang W; Yu M; Xu Y; Xiao Y; Zhou J; Fan J; Li H; Ye Q Am J Cancer Res; 2020; 10(11):3705-3720. PubMed ID: 33294262 [TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711 [TBL] [Abstract][Full Text] [Related]
3. GOLM1 exacerbates CD8 Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203 [TBL] [Abstract][Full Text] [Related]
4. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma. Xie P; Wu M; Wang H; Zhang B; Zhang Z; Yan J; Yu M; Yu Q; Zhao Y; Huang D; Xu M; Xu W; Li H; Xu Y; Xiao Y; Guo L Oncogene; 2024 Oct; 43(42):3108-3120. PubMed ID: 39251847 [TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3. Meng Q; Tian J; Qin F; Huang X; Zhu D; Xiang B; Dong M Transl Cancer Res; 2020 Sep; 9(9):5574-5584. PubMed ID: 35117921 [TBL] [Abstract][Full Text] [Related]
6. GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response. Liang X; Yin Y; Li N Front Genet; 2022; 13():1051168. PubMed ID: 36468024 [No Abstract] [Full Text] [Related]
7. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309 [TBL] [Abstract][Full Text] [Related]
8. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3β/MMPs. Gai X; Tang B; Liu F; Wu Y; Wang F; Jing Y; Huang F; Jin D; Wang L; Zhang H J Genet Genomics; 2019 May; 46(5):235-245. PubMed ID: 31186161 [TBL] [Abstract][Full Text] [Related]
9. GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. Ye QH; Zhu WW; Zhang JB; Qin Y; Lu M; Lin GL; Guo L; Zhang B; Lin ZH; Roessler S; Forgues M; Jia HL; Lu L; Zhang XF; Lian BF; Xie L; Dong QZ; Tang ZY; Wang XW; Qin LX Cancer Cell; 2016 Sep; 30(3):444-458. PubMed ID: 27569582 [TBL] [Abstract][Full Text] [Related]
10. Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma. Chun HW; Hong R Oncol Lett; 2019 Jun; 17(6):5487-5498. PubMed ID: 31186768 [TBL] [Abstract][Full Text] [Related]
11. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357 [TBL] [Abstract][Full Text] [Related]
12. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
13. PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC. Wang X; Liang C; Yao X; Yang RH; Zhang ZS; Liu FY; Li WQ; Pei SH; Ma J; Xie SQ; Fang D Front Pharmacol; 2020; 11():577108. PubMed ID: 33324209 [TBL] [Abstract][Full Text] [Related]
14. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816 [TBL] [Abstract][Full Text] [Related]
15. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541 [TBL] [Abstract][Full Text] [Related]
16. Recent advances of GOLM1 in hepatocellular carcinoma. Yan J; Zhou B; Li H; Guo L; Ye Q Hepat Oncol; 2020 Jun; 7(2):HEP22. PubMed ID: 32647567 [TBL] [Abstract][Full Text] [Related]
17. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Liu J; Liu Y; Meng L; Liu K; Ji B Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705 [TBL] [Abstract][Full Text] [Related]
18. Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma Yu C; Zhang X; Wang M; Xu G; Zhao S; Feng Y; Pan C; Yang W; Zhou J; Shang L; Ma Y Front Oncol; 2023; 13():1198118. PubMed ID: 37324014 [TBL] [Abstract][Full Text] [Related]
19. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792 [TBL] [Abstract][Full Text] [Related]
20. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Chen MH; Jan YH; Chang PM; Chuang YJ; Yeh YC; Lei HJ; Hsiao M; Huang SF; Huang CY; Chau GY Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S616-24. PubMed ID: 23838921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]